Online Event

Annual Online Conference on

Haematology and Blood Disorder Conference

Theme: Simulated health care in the present era of Covid-19

Event Date & Time

Event Location

Online Event

Program Abstract Registration Awards 2020

18 years of lifescience communication


Performers / Professionals From Around The Globe

Tracks & Key Topics



Annual Conference on Hematology and Blood Disorder Conference longing be scheduled on November 03-04, 2020 in London, UK. This congress is exacted to be the most comprehensive and best platform for all the scientists, hematologists, oncologists, pathologists, surgeons, nurses, research scholars, business specialists, students who are working in the field of Hematology

Theme: Simulated health care in the present era of Covid-19

Hematology Congress 2020 will include speaker talks, brief keynote presentations, workshops, and exhibitions, where researchers and associations will exchange ideas and discuss the methodology for new Diagnostics and treatment methods for Hematologic Disorders, Management, and Care of Patients, new approaches emerging in Hematology, etc.

Prestigious, hematologists, Hematology-Oncology educators, postgraduates, connections, and business meanders will gather under the same rooftop. Hematology Conferences and meetings are planned on the subject "Breezes of transformation and substitution in Hematology".

CME Accredited Hematologists 2020 will be directed by EuroSciCon Ltd which is involved in 3000+ Global Events with over 1000+ Conferences, 1200+ Symposiums, and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business, and Management field is organizing conferences all over the globe. EuroSciCon Ltd through its global conferences provides an excellent opening for budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster and Live Streaming, B2B, and Scientific Meetings.


Why Should I Attend?

Conferences yield lots of knowledge with Universities, corporations. It is beneficial to medical trainees and researchers Furthermore for professors and science workroom technicians. Conferences additionally profit and share information among scientists, doctors, and delegates. One company network with a different company and that they share erudition regarding their commodity at the conference. The companies return to attend conferences and show their exhibit before of eminent members and delegates being at the Conference.

Target Audience

  • Hematologists
  • Oncologists
  • Hemato-pathologist
  • Scientists
  • Young Researchers
  • Medical Students
  • Physicians/Consultants/ General Practitioners
  • Nurses
  • Residents
  • Directors/Managers
  • Pathologists
  • Presidents & Vice Presidents/ Directors / Administrators
  • Business Entrepreneurs
  • Hematology Pharma Companies
  • Medical Devices Companies
  • Hematology Associations/ Societies



The hematology diagnostics marketplace was esteemed at US$ 3,167.2 million in 2017 and predictable to scope US$ 5,288.3 million by 2026 at a CAGR of 5.9% throughout the prognostication period from 2018 to 2026.

Globally hematology diagnostics marketplace scope was valued at USD 5.96 billion in 2017. It is predicted to increase at a CAGR of 5.85% over the estimate retro. Aspects such as cumulative pervasiveness of blood disorders tied with collective consciousness about these ailments, and presence of classy & cutting-edge technologies are projected to boost the market progress.
A screenshot of a cell phone

Description automatically generated

Conferring to an artefact issued by Bristol-Myers Squibb, approximately 1 million novel cases of blood malignancy are anticipated to be spotted by 2020, that is estimated to reason for nearly 6.0% of all new-fangled tumors. Besides, a momentous number of the world inhabitants have diverse hemoglobinopathies. High incidence of blood ailments, such that thalassemia is expected to kick the demand for hematology testing.

The advanced investigations in the biomedical segment, exclusively in emerging countries, will boost marketplace development in flow cytometry. Aggregate of radiologists and intensifying attention on the inhibition, and primary diagnosis of ailments will drive the number of medical imaging measures like MRI and CT assessments in hospitals and ASCs across limitless countries. These are predictable to be the chief progress handlers for the global medical imaging components market.
A close up of a computer

Description automatically generated

Key Market Movements

  • Global market of hematology diagnostics is increasing at a CAGR of 5.9% for the retro from 2018 to 2026
  • The hematology analyzer sector displays rewarding progress with boosted applications in the diagnostics trade based on the product type.
  • An increasing number of diagnostic centers, availability of automated analysers with enhanced applications, and increasing test volumes will contribute to the overall growth of the hematology diagnostics market
  • Major players in this vertical are Abbott Laboratories, Bio-Rad Laboratories, Inc., Siemens Healthineers, Mindray Medical International Limited, Danaher Corporation, Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Drew Scientific, Sysmex Corporation, EKF Diagnostics, Boule Diagnostics, HORIBA, Diatron MI Zrt. and others



Track-1: Blood and Hematology

Hematology is the branch of medicine which deals with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. It involves treating diseases which affects the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. Hematology mainly focused on blood components like blood cells, hemoglobin, blood proteins, bone marrow, spleen and Coagulation mechanism. Physicians who work on treating hematologic disorders, referred to as Hematologists.

Blood is a fluid in the body of humans and other animals that delivers necessary substances such as nutrients and oxygen to the cells and transports metabolic waste products away from same cells. In which blood is circulated around the body through blood vessels by the pumping action of the heart.

Track 1-1 Hematologic neoplasms

Track 1-2 Lymphoma

Track 1-3 Hematologic neoplasms

Track 1-4 Blood coagulation Mechanism

Track 1-5 Hematopathology

Track 1-6 Hemophilia

Track 1-7 Prenatal Diagnosis

Track-2: Blood Components and Function

Blood is a body fluid that moves through the vessels of a circulatory system. In humans, it contains plasma, blood cells (red and white blood cells), and cell fragments called platelets. Cells and platelets make up about 45%percent percent of human blood, while plasma makes up the other 55%percent.

Track 2-1 Red Blood Cells

Track 2-2 White Blood Cells

Track 2-3 Platelets

Track 2-4 Plasma

Track 2-5 Blood Cell Production

Track-3: Blood Disorders

Peoples may be affected by many different types of blood conditions and blood cancers. Common blood disorders include anemia, bleeding disorders such as blood clots and hemophilia and blood cancers such as leukemia, lymphoma, and myeloma. It mainly affects red and white blood cells, plasma, and platelets. A larger part of the blood issue is caused by transformations qualities and can be passed to the families. Blood disorders are conditions that affect the blood capacity to work accurately.

Track 3-1 Anemia & Leukemia

Track 3-2 Thalassemia

Track 3-3 Myelodysplastic Syndrome

Track 3-4 Hemophilia

Track-4: Diagnosis, Treatment and Management of Blood Disorders

After the physical examination, for the detection of blood disorders physician usually go for complete blood count. This is the basic test after that to diagnose a person’s blood disorder, the doctor usually must do further blood tests once a consultant finds that something is wrong with one or more of the blood cell types, many additional tests are available for further detection of disease. Doctors can measure proportion of the different types of WBCs and can also determine subtypes of these cells by assessing certain markers on the surface of the cells. Tests are made to measure the ability of white blood cells to fight foreign body infection, to evaluate the functioning of blood platelets and their ability to clot and to check the contents of red blood cells to help determine the cause of anemia or why the cells are not functioning properly. Most of these tests are done on blood samples, but sometime require a bone marrow samples as well for Bone Marrow Examination. Once the problem is diagnosed Hematologists go for the appropriate treatment for the problem.

Track 4-1 Complete Blood Count (CBC)

Track 4-2 Screening Tests

Track 4-3 Bone Marrow Examination and Biopsy

Track 4-4 Bone Marrow Transplantation

Track 4-5 Gene Therapy

Track 4-6 Cord Blood Transplantation

Track-5: Blood Transfusion

Transfusion of blood is the process of receiving whole blood or blood products into one’s systemic circulation intravenously. It may include injection of whole blood or components such as red blood cells, white blood cells, plasma, platelets or clotting factors. Blood transfusion is usually done in cases of deficiencies, to increase the oxygen saturation, during accidents or during surgery, to treat hematologic conditions such as severe anemia, leukemia, and sickle cell disease. Blood transfusion may also be associated with various complications including infections, immunological disorders such as hemolysis or incompatibilities.

Track 5-1 Red and White Blood Cell Transfusion

Track 5-2 Platelet Transfusion

Track 5-3 Autologous Blood

Track 5-4 Reactions of Transfusion

Track 5-5 Testing of Compatibility

Track-6: Blood Transplantations, Thrombosis and Hemostasis

Blood or bone marrow transplant replaces abnormal blood-forming stem cells with healthy cells. When the healthy stem cells come from you, the procedure is called an autologous transplant. When the stem cells come from another person, called a donor, it is an allogeneic transplant.

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. Hemostasis is a process to prevent and stop bleeding, meaning to keep blood within a damaged blood vessel. It is the first stage of wound healing.

Track 6-1 Thromboembolism

Track 6-2 Venous and Arterial Thrombosis

Track 6-3 Vasoconstriction

Track 6-4 Blood coagulation

Track 6-5 Von Willebrand Factor

Track-7: Neuro- Hematology

Hematologic disorders can affect the central and peripheral nervous systems in several different ways, producing a wide range of neurologic disturbances. They result in nervous system disfunction through a variety of mechanisms, including vascular occlusion, hemorrhage, infiltration and metabolic disturbance, which may be hereditary or acquired. Its frequent cause of certain syndromes, such as venous thrombosis, but rarer causes of a wide range of neurologic conditions. Hematologic disease should be considered as a cause of subacute multifocal disorders.

Track 7-1 Thrombophilia

Track 7-2 Thrombocytopenic purpura

Track 7-3 Clonal Disorders

Track 7-4 Sickle cell anemia

Track 7-5 Hypercoagulability and thrombophilia

Track-8: Hematology-Oncology

Hematologic oncology is the branch of medicine concerned with the study, diagnosis, treatment, and prevention of diseases related to blood. Haematology includes the study of etiology. It involves treating diseases that affect the production of blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow, platelets, blood vessels, spleen, and the mechanism of coagulation. The laboratory work that goes into the study of blood is frequently performed by a medical technologist or medical laboratory scientist. Hematologists also conduct studies in oncology and work with oncologists, people who may specialize only in that field instead of both-the medical treatment of cancer. There are various disorders that people are affected by Haematology. A few of these different types of blood conditions that are looked at include Anemia, Hemophilia, general blood clots, bleeding disorders, etc. As for related blood cancers such as Leukemia, myeloma, and lymphoma, these are more serious cases that need to be diagnosed- Myeloma, Myelodysplastic syndromes, Multiple Myeloma, Leukemia, Lymphoma.

Track 8-1 Acute and Chronic Lymphoblastic Leukemia

Track 8-2 Multiple Myeloma

Track 8-3 Hodgkin and Non-Hodgkin Lymphoma

Track 8-4 Myeloid Leukemia

Track 8-5 Myelodysplastic Syndromes

Track-9: Hematologic Malignancies

Hematological malignancies are forms of the cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes. Genetic characterization is vital role in the clinical evaluation of nearly every form of hematologic malignancy. Here, we review how genetic analysis contributes to the diagnosis and/or management of acute leukemias, chronic myeloid neoplasms, B- and T-/natural killer (NK)-cell lymphomas, as well as multiple myeloma.

Track 9-1 Non-Hodgkin Lymphoma

Track 9-2 Acute myeloid leukemia

Track 9-3 Acute lymphoblastic leukemia

Track 9-4 Myeloproliferative Disorders

Track 9-5 Generic drugs

Track-10: Hematology and Pharma industry

The overall market for the hematological pharmaceuticals in top point as it is as often as possible foreseen to be improved over two or three decades. According to the overall market master, the hematology cure and definite market is depended upon to create at the rate of 7.5% from 2015-2020. A portion of the best drug store enterprises creating biological drugs and Generic Drugs fuse. Takeda Oncology, Bristol-Myers Squibb, Boehringer Ingelheim, Roche, Novartis, Celgene, Johnson and Johnson, Lilly, Takeda, AstraZeneca, Merck and Co., Amgen, Janssen bio tech, Pfizer, Bayer, Otsuka, Sanofi, Astellas, Eisai, AbbVie, Pharmacyclics.

Track 10-1 Biological drugs

Track 10-2 Increased investments

Track 10-3 Healthcare expenditures

Track-11: Stem Cell Research

Stem cell research deals with research and publication of high-quality manuscripts related to stem cells. Stem cells are cells of multicellular organisms that can differentiate into other types of cells. They can divide more cells of the same type of stem cells. For a cell to be considered a stem cell, it should be self-renewing and must be either totipotent or pluripotent. Various types of stem cells such as embryonic stem cells, fetal and adult stem cells tissue specific stem cells, haemopoietic stem cells, cancer stem cells are known. Haemopoietic stem cells that give rise to other blood cells by a process called Hemopoiesis in the red bone marrow. Haemopoietic stem cell transplants are used in the treatment of cancers and other immune system disorders.

Track 11-1 Stem cell transplantation

Track 11-2 Tissue regeneration

Track 11-3 Stem cell products

Track 11-4 Stem cell therapy

Track 11-5 Stem cell biomarkers

Track-12: Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. Early on, there are typically no symptoms. Later symptoms may include feeling tired, shortness of breath, easy bleeding, or frequent infections. Some types may develop into acute myeloid leukemia. It causes when exposure to certain chemicals such as tobacco smoke, pesticides, and benzene, and exposure to heavy metals such as mercury or lead.

Track 12-1 Thrombocytopenia

Track 12-2 Stem cell transplantation

Track 12-3 Acute Myelogenous Leukemia

Track-13: Hematologic Therapies

It is the branch of medicine that deals with the study of blood, blood disease and the organs involved in forming blood. The diagnosis and treatment of hematological disorders is mainly managed by specialists in the field referred to as hematologists.

Track-14: Biomarkers in Hematology

Biomarkers in hematology were mostly of protein biomarkers which are useful to detect the tumors early location and mainly to identify bosom growth, these biomarkers simply used to measure and indicate the severity level of disease state. Whereas these hematological biomarkers are helpful in identifying the blood disease. Patients who are suspected with pancreatic malignancy will face CT sweep. Recolors neoplastic pancreatic cells will empower the certainty to identify pancreatic tumor by pathologist and hence suitable for treating disease condition. For pancreatic disease a novel drug discovery in biomarkers like BI-010 and IHC markers are developed.

Track 14-1 Drug Targeting

Track 14-2 Prognosis and treatment production

Track 14-3 Pharmacodynamics and Pharmacokinetics

Track 14-4 Monitoring treatment response

Track 14-5 Acute kidney failure

Track-15: Immunohematology

Immunohematology are commonly known as blood banking is a branch of hematology which studies antigen-antibody reactions and analogous phenomena as they relate to the pathogenesis and clinical manifestations of blood disorders. This is the laboratory medicine dealing with preparing blood components, blood for appropriate selection and transfusion and components that are compatible for transfusion which is helpful for the case of severe blood loss or low blood levels. Red blood cells contain antigens and protein markers on their surfaces, if recipient or donors red blood cells doesn’t contain this antigen the antigen lacking individual will lead to form antibodies which destroys the red blood cells.

Track 15-1 Auto Immune Hemolytic Anemia (AIHA)

Track 15-2 Transfusion related acute lung injury (TRALI)

Track 15-3 Antibody screening

Track 15-4 Clinical immunology

Track-16: Various Aspects of Hematology

Pediatric Haematology is an international peer-reviewed medical journal that covers all aspects of pediatric hematology. The journal covers immunology, pathology, and pharmacology in relation to blood diseases in children and shows how basic experimental research can contribute to the understanding of clinical problems. Physicians specialized in hematology are known as hematologists. Their routine work mainly includes the care and treatment of patients with hematological diseases, although some may also work at the hematology laboratory viewing blood films and bone marrow slides under the microscope, interpreting various hematological test results and blood clotting test results. In some institutions, hematologists also manage the hematology laboratory. Physicians who work in hematology laboratories, and most commonly manage them, are pathologists specialized in the diagnosis of hematological diseases, referred to as hematopathologists.

Track 16-1 Clinical Hematology and Hematopathology

Track 16-2 Experimental Hematology and Ethical Issues

Track 16-3 Scope of Animal Haematology and Its Importance

Track 16-4 Hematology practice and Case Reports

Track 16-5 Contribution of Blood Banks and Blood Donation Programs

Track 16-6 Prospects of Hematology Research

Track-17: Blood Based Products

A blood product may be defined as a therapeutic substance that is acquired from human blood. Some of the blood products are: Whole blood - which is rarely used in transfusion medicine. Blood components - Suspension of red blood cells, white blood cells and platelets; Plasma derivatives - Plasma proteins such as albumin, coagulation factor suspension and immunoglobulins.

Track-18: Molecular Typing of Blood

Blood group antigens are polymeric residues of protein or carbohydrates on the red cell surface. They can provoke an antibody response in individuals who lack them, and some antibodies can lead to hemolytic transfusion reaction or hemolytic disease of the newborn. Researchers have identified the molecular basis of many red cell blood group antigens, and an actively maintained database currently lists over 1,600 alleles of 44 genes. This mini review describes the major applications of the explosion knowledge in blood group genetics to the practice of blood banking and transfusion medicine.

Track 18-1 Fetal Typing

Track 18-2 Transfused patients

Track 18-3 Immunoglobulin coated red cells

Track 18-4 RHD Zygosity

Track 18-5 Tests and Treatment for Anemia

Track-19: Anemia in Pregnancy

During pregnancy, anemia may developed. When women having anemia during pregnancy time,  their blood doesn't have enough healthy red blood cells to carry oxygen to your tissues and to  their baby. During pregnancy, body produces more blood to support the growth of your baby. If you're not getting enough iron or certain other nutrients, your body might not be able to produce the amount of red blood cells it needs to make this additional blood. It’s normal to have mild anemia when you are pregnant. But you may have more severe anemia from low iron or vitamin levels or from other reasons. Anemia can leave you feeling tired and weak. If it is severe but goes untreated, it can increase your risk of serious complications like preterm delivery. Here’s what you need to know about the causes, symptoms, and treatment of anemia during pregnancy.

Track 19-1 Types of Anemia During Pregnancy

Track 19-2 Risk Factors During Pregnancy

Track 19-3 Symptoms

Track-20: Automated Hematology

Hematology automation has progressed steadily since Wallace Coulter first applied electrical impedance technology to counting red cells and white cells. By the 1980s, most hematology laboratories were reporting out a 7-parameter complete blood count (CBC) and three-part differential obtained from a single aspiration on a stand-alone, bench-top instrument. Eventually, this process was upgraded even further when it became possible to obtain these results without uncapping the sample. When this became state-of-the-art, CBC turnaround time (TAT) was primarily dependent on how fast a laboratorian could do a manual 100-cell differential and/or a manual reticulocyte count.

Track 20-1 Clinical Decision Making

Track 20-2 Standardization

Track 20-3 Cross Training



Global Hematology Societies:

European Hematology Societies:

International of Hematology, European of HematologyBritish Society of Hematology, European of Pediatric Hematology Oncology, European Society of Surgical Oncology, Association of European Cancer LeaguesEuropean Academy of Cancer Sciences, European Prostate Cancer Coalition, Organization of European Cancer Institute, European Organization for Research and Treatment of Cancer, International Society of Pediatric Oncology

Hematology Societies in South Africa:

CHOC Childhood Cancer Foundation, African Cancer Registry Network, African Journal of Cancer, Mediterranean Oncology Society, South African Society of Haematology, African Women’s Cancer Awareness Association, Haematology and Oncology Society of Africa, World Health Organization Africa

Hematology Societies in Asia-Pacific:

Asian Cancer Foundation, Asia Pacific Hematology Consortium, Asian Society of Gynecologic Oncology, Cancer Therapeutics Research Group, Black Sea Countries Coalition on Breast and Cervical Cancer Prevention, Asian Hematology Association, The Thai Society of Hematology, Asian and Pacific Federation of Organizations for Cancer Research and Control, Asian Clinical Oncology Society: ACOS, Asian Fund for Cancer Research, Australasian Lung Cancer Trials Group, Japanese Society of Hematology, Pan Arab Hematology Association.

Hematology Societies in USA:

American Cancer Society, American Brain Tumor Association, Association of Community Cancer Centers, American Childhood Cancer Organization, American Society for Radiation Oncology, International Society on Thrombosis and Hemostasis Inc.,  Childhood Brain Tumor Foundation, Michigan Society of Hematology and Oncology, Lymphoma Research Foundation, The Canadian Hematology Society, American Society of Hematology, International Society for Laboratory HematologyMichigan  of Hematology, American Society of Clinical Oncology

Latest Updates/News on Medical Research:

Experimental Immunotherapy can put patients with relapsed or refractory lymphoma into remission:

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. Let’s have a brief discussion on this in London at Hematology 2020 conference. Best platform you have ever experienced.


PARTICIPATION OPTIONS: Hematology 2020, provides the participants with different modes or ways to participate under either ACADEMIC / STUDENT / BUSINESS Category.

Keynote speaker: 45-50 minutes:

Speaker (oral presentation): 25-30 minutes (only one person can present)

Speaker (workshop): 45-50 minutes (more than 1 can present)

Speaker (special session): 45-50 minutes (more than 1 can present)

Speaker (symposium): more than 45 minutes (more than 1 can present)

Delegate (only registration): will have access to all the sessions with all the benefits of registration

Poster presenter: can present a poster and enjoy the benefits of delegate

Remote attendance: can participate via video presentation or e-poster presentation

Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes

Media partner



For more details about each mode, kindly contact: [email protected]

WhatsApp office: +44-20-33182512


This Live conference is accredited with CPD credits.

Attend Keynote Presentation by world’s most eminent researchers

Access to all the sessions

Get OCM certificate

Get worldwide acknowledgment to your profile and Research

Get your abstracts published with unique DOI in International Journals

Get up to 50% discounts for publishing your entire article in our open access International Journals

Get Handbooks and conference kits

Get an access to the network with eminent personalities from worldwide





Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!